translocase of inner mitochondrial membrane 17AGenealiases: TIM17 · TIM17A
Q-omics provides the consensus-scored TIMM17A profile across patient tissues and cancer cell-line models. TIMM17A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TIMM17A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TIMM17A protein abundance shows 28,811 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where TIMM17A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM17A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM17A survival associations across molecular data types. TIMM17A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM17A RNA expression–survival associations across cancer types. High TIMM17A expression shows unfavorable associations in UVM, ACC, LUAD, ESCA, HNSC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TIMM17A RNA expression.
This table summarizes TIMM17A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TIMM17A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM17A shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, BRCA and LUAD. The HNSC box plot shows higher TIMM17A RNA expression in tumor versus normal tissue (log2 FC = +0.815, t-test p < 0.001).
This table shows molecular features associated with TIMM17A in patient tissues and cancer cell lines. In patient samples, TIMM17A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMM17A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
